<DOC>
	<DOC>NCT01396447</DOC>
	<brief_summary>The objective of this study was to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of patients with bipolar depression.</brief_summary>
	<brief_title>Safety, Tolerability, and Efficacy of Cariprazine in Patients With Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Patients who have provided informed consent prior to any study specific procedures. Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR) criteria for bipolar I disorder as confirmed by the Structured Clinical Interview (SCID) for DSMIVTR bipolar I depression without psychotic features. Patients with normal physical examination, laboratory, vital signs,and/ or echocardiogram (ECG). Verified previous manic or mixed episode. Patients with a total Hamilton Rating Scale for Depression (HAMD)17 score ≥ 20. Patients with a HAMD17 item 1 score ≥ 2. Patients with a Clinical Global Impression of Severity (CGIS) score ≥ 4. Patients with a DSMIVTR diagnosis of an axis I disorder other than bipolar I disorder that was the primary focus of treatment within the previous 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Bipolar I Disorder</keyword>
	<keyword>Bipolar Depression</keyword>
	<keyword>Depression</keyword>
	<keyword>Bipolar Disorder</keyword>
</DOC>